Design Therapeutics Stock Options
| DSGN Stock | USD 4.65 0.01 0.22% |
Design Therapeutics' latest option contracts expiring on April 17th 2025 are carrying combined implied volatility of 2.57 with a put-to-call open interest ratio of 0.01 over 10 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on April 17th 2025.
Open Interest Against April 17th 2025 Option Contracts
2025-04-17
The chart above shows Design Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Design Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Design Therapeutics' option, there is no secondary market available for investors to trade.
In The Money vs. Out of Money Option Contracts on Design Therapeutics
Analyzing Design Therapeutics' in-the-money options over time can help investors to take a profitable long position in Design Therapeutics regardless of its overall volatility. This is especially true when Design Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Design Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Design Therapeutics' stock while costing only a fraction of its price.
Please note that buying 'in-the-money' options on Design Therapeutics lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Design Therapeutics' value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Design Therapeutics contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Design Stock moves the wrong way.
Design Therapeutics In The Money Call Balance
When Design Therapeutics' strike price is surpassing the current stock price, the option contract against Design Therapeutics stock is said to be in the money. When it comes to buying Design Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Design Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Design Current Options Market Mood
Design Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Design Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Design Therapeutics' options investors are not very successful. Design Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Design contract
Base on the Rule 16, the options market is currently suggesting that Design Therapeutics will have an average daily up or down price movement of about 0.16% per day over the life of the 2025-04-17 option contract. With Design Therapeutics trading at USD 4.65, that is roughly USD 0.007469. If you think that the market is fully incorporating Design Therapeutics' daily price movement you should consider buying Design Therapeutics options at the current volatility level of 2.57%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Design |
Purchasing Design Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Design calls. Remember, the seller must deliver Design Therapeutics stock to the call owner when a call is exercised.
Design Therapeutics Option Chain
When Design Therapeutics' strike price is surpassing the current stock price, the option contract against Design Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Design Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Design. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Design. It also shows strike prices and maturity days for a Design Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | DSGN250417C00012500 | 0 | 12.5 | 0.0 - 1.2 | 1.2 | |
Call | DSGN250417C00010000 | 1 | 10.0 | 0.0 - 1.25 | 0.5 | Out |
Call | DSGN250417C00007500 | 222 | 7.5 | 0.0 - 0.5 | 0.2 | Out |
Call | DSGN250417C00005000 | 29 | 5.0 | 0.0 - 1.75 | 0.58 | Out |
Call | DSGN250417C00002500 | 24 | 2.5 | 1.3 - 3.7 | 2.54 | In |
Put | DSGN250417P00002500 | 0 | 2.5 | 0.0 - 1.3 | 1.3 | |
Put | DSGN250417P00005000 | 2 | 5.0 | 0.0 - 1.05 | 0.95 | In |
Put | DSGN250417P00007500 | 0 | 7.5 | 1.6 - 3.1 | 1.6 | In |
Put | DSGN250417P00010000 | 0 | 10.0 | 4.6 - 5.6 | 4.6 | In |
Put | DSGN250417P00012500 | 0 | 12.5 | 6.4 - 8.7 | 6.4 | In |
Design Total Stockholder Equity
Total Stockholder Equity |
|
Design Therapeutics Corporate Management
| Aseem Ansari | CoFounder Advisor | Profile | |
| Sean Jeffries | Chief Officer | Profile | |
| Elizabeth Gordon | Senior Affairs | Profile | |
| Mustapha Parekh | General Counsel | Profile | |
| Joo MD | CEO Pres | Profile | |
| MD FACC | Consulting Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.